EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

APTIMA mRNA vs. DNA-Based HPV Assays: Analytical Performance Insights from a Resource-Limited South African Setting

Varsetile Varster Nkwinika iD, Kelvin Amoh Amissah, Johnny Nare Rakgole, Moshawa Calvin Khaba iD, Cliff Abdul Magwira iD, Ramokone Lisbeth Lebelo iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Varsetile Varster Nkwinika und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virological Pathology, Sefako Makgatho Health Sciences University, Medunsa, P.O. Box 60, Pretoria 0204, South Africa. Hauptthemen laut MEDLINE: Papillomavirus Infections, Uterine Cervical Neoplasms, DNA, Viral, RNA, Messenger. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Laboratory Service, Vlaamse Interuniversitaire Raad, National Health Laboratory Service (NHLS) Research Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer remains a major health burden among women in sub-Saharan Africa, where screening is often limited. Persistent high-risk human papillomavirus (HR-HPV) infection is the principal cause, highlighting the need for accurate molecular diagnostics. This cross-sectional study evaluated the analytical performance of one mRNA assay, APTIMA® HPV assay (APTIMA mRNA), and two DNA-based assays, the Abbott RealTime High Risk HPV assay (Abbott DNA) and Seegene Allplex™ II HPV28 assay (Seegene DNA), in 527 cervical samples from a South African tertiary hospital, focusing on 14 shared HR-HPV genotypes. Seegene DNA yielded the highest detection rate (53.7%), followed by Abbott DNA (48.2%) and APTIMA mRNA (45.2%). APTIMA mRNA showed a strong agreement with Abbott DNA (87.9%, κ = 0.80), 89.9% sensitivity, 91.2% NPV, and the highest accuracy (AUC = 0.8804 vs. 0.8681). The agreement between APTIMA mRNA and Seegene DNA was moderate (83.4%, κ = 0.70), reflecting target differences. Many DNA-positive/mRNA-negative cases likely represent transient infections, though some may be latent with reactivation potential, warranting a follow-up. In resource-constrained settings, prioritizing transcriptionally active infections through mRNA testing may enhance screening efficiency and reduce burden. Scalable, cost-effective assays with strong clinical utility are essential for broadening access and improving cervical cancer prevention. Further studies should assess the integration of mRNA testing into longitudinal screening algorithms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsUterine Cervical NeoplasmsDNA, ViralRNA, MessengerPapillomaviridaeMolecular Diagnostic TechniquesHumansFemaleSouth AfricaAdultCross-Sectional StudiesMiddle AgedSensitivity and SpecificityGenotypeYoung Adult

Stichwörter der Autor:innen

E6/E7 mRNAHPV DNASouth Africaanalytical performancecervical cancer screening

Substanzen

DNA, ViralRNA, Messenger

Autor:innen und Institutionen

  • Department of Virological Pathology, Sefako Makgatho Health Sciences University, Medunsa, P.O. Box 60, Pretoria 0204, South Africa.
  • South African Vaccination and Immunisation Centre (SAVIC), Sefako Makgatho Health Sciences University, Medunsa, P.O. Box 60, Pretoria 0204, South Africa.
  • Department of Anatomical Pathology, Sefako Makgatho Health Sciences University, Medunsa, P.O. Box 60, Pretoria 0204, South Africa.
  • National Health Laboratory Service (NHLS), Department of Anatomical Pathology, Sefako Makgatho Health Sciences University, Medunsa, P.O. Box 60, Pretoria 0204, South Africa.
  • National Health Laboratory Service (NHLS), Department of Virological Pathology, Sefako Makgatho Health Sciences University, Medunsa, P.O. Box 60, Pretoria 0204, South Africa.

ORCID-Profile: Varsetile Varster Nkwinika, Moshawa Calvin Khaba, Cliff Abdul Magwira, Ramokone Lisbeth Lebelo

Förderung

  • National Health Laboratory Service
  • Vlaamse Interuniversitaire Raad
  • National Health Laboratory Service (NHLS) Research Trust

Zitieren

APA

Nkwinika, V. V., Amissah, K. A., Rakgole, J. N., Khaba, M. C., Magwira, C. A., & Lebelo, R. L. (2025). APTIMA mRNA vs. DNA-Based HPV Assays: Analytical Performance Insights from a Resource-Limited South African Setting. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157450

Vancouver

Nkwinika VV, Amissah KA, Rakgole JN, Khaba MC, Magwira CA, Lebelo RL. APTIMA mRNA vs. DNA-Based HPV Assays: Analytical Performance Insights from a Resource-Limited South African Setting. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157450

BibTeX
@article{Nkwinika2025,
  author = {Nkwinika, Varsetile Varster and Amissah, Kelvin Amoh and Rakgole, Johnny Nare and Khaba, Moshawa Calvin and Magwira, Cliff Abdul and Lebelo, Ramokone Lisbeth},
  title = {APTIMA mRNA vs. DNA-Based HPV Assays: Analytical Performance Insights from a Resource-Limited South African Setting},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157450}
}
Kostenlos starten →